| Name | Title | Contact Details |
|---|
QualCare, Inc., one of the region`s leading providers of health care coverage, provides the public and private marketplace with a higher-quality, lower-cost alternative to commercial insurance companies. QualCare`s network covers over 100 acute, specialty and rehabilitation hospitals, as well as over 31,000 physicians and other ancillary providers across New Jersey, New York and Pennsylvania. Founded in 1991 from a consortium of hospital systems, QualCare has experienced dramatic growth over the past two decades. Currently, 16 of New Jersey`s largest and most successful hospitals own and serve on QualCare`s Board of Directors. QualCare services over 900,000 members, with a clientele that spans health systems, unions, local governments, school boards, small to large businesses and some of New Jersey`s largest corporations. With rate increases that are consistently below industry standards and unparalleled service satisfaction, QualCare is well positioned to succeed in the changing healthcare industry.
BioAtla was founded in 2007 and employs deep expertise in protein engineering to develop better monoclonal antibody and other protein therapeutics. Our suite of proprietary technologies (protected by more than 70 issued patents and patent applications) has enabled us to develop dozens of novel therapeutic proteins for our partners and our own pipeline. We accelerate the process from target discovery to manufacturing and preclinical studies by creating drugs with more selective targeting, greater affinity, and more cost-efficient and predictable manufacturing. In the process we also create valuable, protectable IP that gives our partners significant competitive advantage. The culmination of our protein evolution technologies is our Conditionally Active Biologics (CAB)platform. Monoclonal antibodies or enzymes can be engineered for selective conditional activation, i.e. the protein`s functions are designed to modulate with changes in microphysical conditions (e.g., pH level, oxidation, temperature, pressure concentration, presence of certain ions, hydrophobicity and competing protein binding). Tumors and other kinds of diseased tissue give rise to unique localized conditions distinct from normal tissue. CAB designed monoclonal antibodies can be programmed to deliver an ADC payload and/or recruit the immune response to specific sites and conditions in the body.
NexMed, Inc. (NASDAQ: NEXM), due to its recent acquisition of Bio-Quant, Inc., a revenue-generating specialty contract research organization performing in vitro and in vivo pharmacology services, is now the largest specialty CRO based in San Diego, CA.
whites shrimp dock is a Saint Helena Island, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Manitoba Institute of Child Health is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.